News & Updates
Showing Urology articles
Showing
Intravesical pembrolizumab delivers antitumour activity in NMIBC
A recent first-in-human study has shown that directly applying pembrolizumab to the bladder is a safe and effective treatment option for patients with nonmuscle-invasive bladder cancer (NMIBC) who are unresponsive to bacillus Calmette-Guérin (BCG) treatment.
Tension-free vaginal tape for stress incontinence safe, effective in long term
Among women with stress urinary incontinence, the retropubic tension-free vaginal tape (TVT) retains its efficacy up to 24 years after initial placement, with adverse effects being uncommon and having a low impact on quality of life, according to a study.
Triplet therapy with ARSI, docetaxel, ADT boosts survival in mHSPC
Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.
Chemoablative gel preferrable over surgery in adults with nonmuscle-invasive bladder cancer
UGN-102, a nonsurgical, chemoablative gel used as a primary treatment for nonmuscle-invasive bladder cancer (NMIBC), is more patient-centred than standard treatments, according to a recent study.
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.
